Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals

NCT05245890 | Unknown

• 1 other identifier: uric acid trajecteries2022
• Study Type: observational
• Target: 2,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders. A growing body of evidence, comprising a great deal of cross-sectional studies and several prospective ones, also indicates that hyperuricemia is associated with increased prevalence, incidence, and disease severity of non-alcoholic fatty liver disease (NAFLD). Capitalizing on a cohort study in China, the investigators are aimed to assess the associations of SUA trajecteries with remission of NAFLD in NAFLD individuals and examined whether the association differs across subpopulations.

Conditions

Non-Alcoholic Fatty Liver Disease; Hyperuricemia

Outcome Measures

Primary Outcomes (1)

• the severity fatty liver evaluated by hepatic ultrasonic examination

  Hepatic ultrasonic examination was performed in all subjects by a trained ultrasonographist who was unaware of the clinical and laboratory data. Hepatic steatosis was diagnosed by characteristic echo patterns according to conventional criteria, such as the evidence of diffuse hyperechogenicity of the liver relative to the kidneys, ultrasound beam attenuation, and poor visualization of intrahepatic structures.

  2 years

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

People who undergo annual physical examinations in The First Affiliated Hospital, College of Medicine, Zhejiang University are enrolled in this study. People are divided into two groups according to hepatic ultrasonic examination at baseline: (1) individuals with NAFLD; (2) individuals without NAFLD.

You may qualify if:

• age \>=18 years;
• agree to be enrolled in this study.

You may not qualify if:

• those taking antihypertensive or antidiabetic agents, lipid-lowing agents, or hypouricemic agents;
• those with alcohol consumption greater than 140 g/week for men and 70 g/week for women;
• those with a history of other known causes of chronic liver disease such as viral hepatitis or autoimmune hepatitis, and those using hepatotoxic medications.

Sponsors & Collaborators

• Ningbo No. 1 Hospital: lead
• The First Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China: collaborator

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease; Hyperuricemia

Condition Hierarchy (Ancestors)

Fatty Liver; Liver Diseases; Digestive System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2022
• First Posted: February 18, 2022
• Study Start: March 1, 2022
• Primary Completion: March 1, 2023
• Study Completion: March 1, 2024
• Last Updated: February 18, 2022

Record last verified: 2022-02

Data Sharing

• IPD Sharing: Will not share